Αρχική ASCO Meeting Abstracts ASCO Meeting Abstracts

ASCO Meeting Abstracts

print
email

 

Implications of KRAS status in first-line chemotherapy with bevacizumab in advanced colorectal cancer: A phase IV study of Hellenic Oncology Research Group (HORG). AuthorsAnna Koumarianou, Nikolaos Ziras, Stylianos Kakolyris, Michael Vaslamatzis, Aristidis Polyzos, Nikolaos K. Kentepozidis, Athina Christopoulou, Spyros Xynogalos, Athanasios Athanasiadis, Ilias Athanasiadis, Athanasios Anagnostopoulos, Athanasios Karampeazis, Christos E. Emmanouilides, Ioannis Boukovinas, Paris Makrantonakis, Charalambos Kouroussis, Efthimios Prinarakis, Dora Hatzidaki, Vassilis Georgoulias; Hellenic Oncology Research Group (HORG), Athens, Greece; Hellenic Oncology Research Group (HORG), Athens, AZ, Greece.J Clin Oncol 36, 2018 (suppl; abstr e15521)http://abstracts.asco.org/214/AbstView_214_220989.html

Phase II study of cabazitaxel as second-line treatment in patients with HER-2 negative metastatic breast cancer previously treated with taxanes. Authors: Angelos Koutras, Flora Zagouri, Georgia-Angeliki Koliou, Georgios Lazaridis, Dimitrios Tryfonopoulos, Athanasios Kotsakis, Eleni Res, Nikolaos K. Kentepozidis, Evangelia Razis, Amanda Psyrri, Georgios Koumakis, Haralabos Kalofonos, George Fountzilas, Meletios A. Dimopoulos; Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece. J Clin Oncol 36, 2018 (suppl; abstr 1089). http://abstracts.asco.org/214/AbstView_214_224945.html

ISO-CC-005: A phase I/II study of Modufolin (MTHF) in combination with 5-FU, irinotecan, and oxaliplatin ± bevacizumab in patients with metastasizing colorectal cancer. Authors: Helena Anna Taflin, Karin M E Ganlov, Tormod Kyrre Guren, Christos Papadimitrou, Nikolaos K. Kentepozidis, Johan Haux, Per Pfeiffer, Goran Ulf Carlsson; Sahlgrenska University Hospital, Gothenburg, Sweden; Isofol Medical AB, Gothenburg, Sweden; Oslo University Hospital, Oslo, Norway; University of Athens, Aretaieio Hospital, Athens, Greece; Hellenic Airforce General Hospital, Athens, Greece; Skaraborgs Hospital/Skovde, Skovde, Sweden; Odense University Hospital, Odense, Denmark. J Clin Oncol 36, 2018 (suppl 4S; abstr 838).

Three versus six months adjuvant oxaliplatin plus fluoropyrimidine chemotherapy for patients with stage III colon cancer: The Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant (IDEA) chemotherapy  project. Authors: John Souglakos, Ioannis Boukovinas, Spyros Xynogalos, Stylianos Kakolyris, Nikolaos Ziras, Michael Vaslamatzis, Alexandros Ardavanis, Athanasios Athanasiadis, Nikolaos E. M. Androulakis, Nikolaos K. Kentepozidis, Athina Christopoulou, Paris Makrantonakis, Ioannis I. Varthalitis, Charalampos Christofyllakis, Christos E. Emmanouilides, Dimitrios Mavroudis, Efthimios Prinarakis, Aggeliki Kalisperi, Dora Hatzidaki, Vassilis Georgoulias; Hellenic Oncology Research Group, Athens, Greece. J Clin Oncol 36, 2018 (suppl 4S; abstr 730)  https://meetinglibrary.asco.org/record/155659/abstract

Phase II trial of modified FOLIRI plus Panitumumab as first-line treatment in elderly patients with RAS wild-type metastatic colorectal cancer. Author(s): Athanasios Karampeazis, Lampros Vamvakas, Nikolaos K. Kentepozidis, Athanasios Kotsakis, Kostas Kalbakis, Spyros Xynogalos, Ioannis Sougklakos, Christos E. Emmanouilides, Alexandra Voutsina, Dora Hatzidaki, Vassilis Georgoulias; Hellenic Oncology Research Group (HORG), Athens, GreeceJ , Clin Oncol 35, 2017 (suppl; abstr e15053) http://abstracts.asco.org/199/AbstView_199_192537.html

The Greek participitation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study of 3 versus 6 months of adjuvant chemotherapy in stage III colon cancer: Patients’ characteristics and safety analysis. John Souglakos, Ioannis Boukovinas, Stylianos Kakolyris, Nikolaos Ziras, Nikolaos E. M. Androulakis, Alexandros Ardavanis, Nikolaos K. Kentepozidis, Michael Vaslamatzis, Athanasios Athanasiadis, Athina Christopoulou, Paris Makrantonakis, Aristidis Polyzos, Dimitrios Mavroudis, Anastasia Mala, Aggeliki Kalisperi, Spyros Xynogalos, Ioannis I. Varthalitis, Charalambos Kouroussis, Efthimios Prinarakis, Vassilis Georgoulias; Hellenic Oncology Research Group (HORG), Athens, Greece, J Clin Oncol 35, 2017 (suppl 4S; abstract 740)

Salvage treatment of relapsed/refractory small cell lung cancer with pazopanib: A Hellenic Oncology Research Group’s (HORG) phase II study. Athanasios Kotsakis,   Vasilis Karavasilis, Sofia Agelaki, Nikolaos K. Kentepozidis, Stavros Peroukidis, Epaminontas Samantas, Charalampos Christofyllakis, Eleftheria- Kleio Dermitzaki, Filippos Koinis, E Hartabilas, George Fountzilas, Efthimios Prinarakis, Vassilis Georgoulias; Hellenic Oncology Research Group (HORG), Athens, Greece, J Clin Oncol 34, 2016 (suppl; abstr 8561)

    1.  
  1.  
    1.  
  1.  
    1.  
  1.  
    1.  
  1.  
    1.  
  1.  
     
  1.  
     
  1.  
    1.  
  1.  
    1.  
  1.  

 

    1.  
  1.  
     
  2.  
     
  3.  

 

Έχει διαβαστεί 2761 φορές

Ημερολόγιο

Ογκολόγοι Κεντεποζίδης

ΓΡΗΓΟΡΗ ΕΠΙΚΟΙΝΩΝΙΑ

Ογκολόγοι Δρ. Ν. Κεντεποζίδη

Βασ. Σοφίας 102, Αθήνα 11527

Τηλ. Ιατρείου    +30 210 7258409

Τηλ. Ραντεβού  +30 6970039500